TRANSCAN-3 aims at coordinating investment in identified common priority areas of cancer research that contributes to significant advances in cancer prevention, detection, diagnosis, treatment, and quality of life for patients.
In a global setup in which funding resources are limited, the TRANSCAN network has demonstrated to achieve added value and critical mass for a well-organized model of transnational cooperation by supporting high-impact translational cancer research through joint calls for proposals, and by an efficient investment of dedicated national/regional public funding, leveraged with foundation/charity-based resources and EU financial support.
In this phase, TRANSCAN-3 plans to implement at least four joint transnational calls in a five-year period. The level of financial resources pooled for each of the joint calls is expected to be analogous to that of the first one which was co-funded by the EU core funding thus reaching a total budget of ~€ 80M.
The scientific topics of the additional joint transnational calls will be defined based on common research priorities and taking into consideration international developments where relevant as well as with the involvement of patient organisations and other key stakeholders across the cancer research spectrum.
Furthermore, research and innovation priorities will be identified through the analysis of EU-funded on-going actions under Horizon 2020 and by complementing interactions with European and international initiatives in the field of cancer research, such as the Horizon Europe Cancer Mission, to avoid any overlapping with other cancer-related on-going actions.